Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease

Journal of Dermatology

Volumn 40, Issue 11, 2013, Pages 923-926

  Torres, Tiago ^a,b   Sales, Rita ^b   Vasconcelos, Carlos ^a,b   Martins Da Silva, Berta ^b   Selores, Manuela ^a,b  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

cardiovascular disease; cardiovascular risk factors; Framingham Risk Score; psoriasis; treatment goals

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PSORIASIS; RISK ASSESSMENT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84886953964     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12267     Document Type: Article

References (15)

1. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 30: 496-509.
2. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
3. Gisondi P, Girolomoni G,. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-324.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB,. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
6. Peters MJ, Symmons DP, McCarey D, et al,. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331.
7. Mehta NN, Yu Y, Pinnelas R, et al,. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: e1-e6.
8. Mehta NN, Krishnamoorthy P, Yu Y, et al,. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol 2012; 67: 796-798.
9. Grundy SM, Cleeman JI, Merz CN, et al,. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110: 227-239.
10. Rosendorff C, Black HR, Cannon CP, et al,. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007; 115: 2761-2788.
11. Hennekens CH, Dalen JE,. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med 2013; 126: 373-378.
12. Kimball AB, Szapary P, Mrowietz U, et al,. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 67: 76-85.
13. Grundy SM, Cleeman JI, Daniels SR, et al,. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
14. D'Agostino RBS, Grundy S, Sullivan LM, et al,. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
15. Gisondi P, Farina S, Giordano MV, et al,. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754-1757.